Subscribe to Updates

    Get the latest creative news from FooBar about art, design and business.

    What's Hot

    Under the Patronage of His Highness the Minister of Culture, the ‘Saudi Film Confex’ is Inaugurated in Riyadh

    October 2, 2023

    Amazon drought results in over 100 dolphin deaths

    October 2, 2023

    Maritime’s green future priced at $28 billion annually until 2050 by UNCTAD

    September 29, 2023
    Facebook X (Twitter) Instagram
    • Home
    • Contact Us
    Addis Ababa WeeklyAddis Ababa Weekly
    • Automotive
    • Business
    • Entertainment
    • Health
    • Lifestyle
    • Luxury
    • News
    • Sports
    • Technology
    • Travel
    Addis Ababa WeeklyAddis Ababa Weekly
    Home » Early results of a study on an Alzheimer’s drug show promise
    Health

    Early results of a study on an Alzheimer’s drug show promise

    September 30, 2022
    Facebook Twitter Pinterest LinkedIn Tumblr WhatsApp Email

    The shares of Biogen and other drugmakers researching Alzheimer’s disease surged Wednesday after Japan’s Eisai Co. Ltd.. reported its potential treatment appeared to slow the disease in a late-stage study. Lecanemab, the drugmaker’s treatment, reduced patients’ clinical decline by 27% after 18 months of infused treatment compared to placebos or fake drugs, according to AP reports.

    Early results of a study on an Alzheimer's drug show promiseThe results of Eisai’s global study of nearly 1,800 people with early-stage Alzheimer’s were announced late Tuesday. Mental decline and ability to do daily activities such as dressing and eating were measured using a scale. Eisai Co. Ltd. said it would present full research results at a conference in late November. The findings will also be published in a peer-reviewed medical journal.

    The company is already seeking an accelerated approval from the U.S. Food and Drug Administration, and the agency is expected to decide by early next year. Biogen and Eisai will jointly promote the drug. Researchers usually caution against evaluating a study before full results are released. According to Mizuho Securities analyst Graig Suvannavejh, the initial findings are “quite robust” and support regulatory approval.

    According to the Alzheimer’s Association, the findings provide the highest hope so far for treating the disease’s underlying causes. Alzheimer’s disease affects some 6 million Americans and many more worldwide, gradually destroying parts of the brain that control memory, reasoning, communication, and basic daily functions.

    There is no known cure for Alzheimer’s disease. Researchers are still trying to understand what causes the disease, and long-standing treatments only manage symptoms. It has been nearly two decades since Biogen introduced a new Alzheimer’s drug. However, it has generally flopped after debuting at $56,000 annually, which Biogen later reduced. Due to weak evidence that the drug slows Alzheimer’s progression, doctors have been hesitant to prescribe it. Due to the drug’s high price and uncertain benefits, insurers have blocked or restricted coverage.

    Share. Facebook Twitter Pinterest LinkedIn Tumblr WhatsApp Email

    Related Posts

    New research warns of liver risk from daily soda consumption

    September 6, 2023

    Sheesha cafes are a lethal mix of health risks and idle talk

    September 6, 2023

    Blue Zone centenarians’ longevity linked to high-carb diet

    September 1, 2023

    Cholesterol – the silent killer and Its Impact on hearing

    August 29, 2023

    The dynamic science behind the static plank

    August 28, 2023

    WHO raises alert on EG.5 Coronavirus variant in the US and UK

    August 10, 2023
    Latest News

    Amazon drought results in over 100 dolphin deaths

    October 2, 2023

    Maritime’s green future priced at $28 billion annually until 2050 by UNCTAD

    September 29, 2023

    World Tourism Day 2023 calls for sustainable growth in tourism

    September 26, 2023

    UAE and India discuss strategic ties at UNGA78 in New York

    September 26, 2023

    Leaders of UAE and Netherlands convene to reinforce mutual cooperation

    September 26, 2023

    From India to Brazil, leadership transition marks G20 Summit’s conclusion

    September 11, 2023

    African Union Inducted into G20 on India’s Initiative

    September 9, 2023

    Biden and Modi cement ties as India ascends global stage

    September 9, 2023
    © 2021 Addis Ababa Weekly | All Rights Reserved
    • Home
    • Contact Us

    Type above and press Enter to search. Press Esc to cancel.